Loading organizations...
Based in Cambridge, Massachusetts, Etiome is a biotechnology company that develops an artificial intelligence platform to detect early disease progression and create preemptive medicines. The firm utilizes its Temporal Biodynamics system to analyze complex biological data and identify the silent stages of chronic conditions, such as Parkinson's disease, Alzheimer's disease, and various cancers. Emerging from stealth mode after four years of platform development, the enterprise operates with a $50 million initial funding commitment from lead investor Flagship Pioneering, the venture creation firm behind Moderna. The organization focuses on developing targeted therapeutic interventions that halt metabolic, neurodegenerative, and autoimmune diseases before they become severe, operating under the leadership of current chief executive officer Adrian Rawcliffe. Etiome was officially founded in 2021 by Flagship Pioneering executives Noubar Afeyan and founding chief executive officer Avak Kahvejian.
Etiome has raised $50.0M across 1 funding round.
Etiome has raised $50.0M in total across 1 funding round.
Etiome has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $50M Series A | — | Flagship Pioneering | Announced |
Etiome has raised $50.0M in total across 1 funding round.
Etiome's investors include Flagship Pioneering.
Etiome is a biotechnology startup launched by Flagship Pioneering in 2021, emerging from stealth in late 2025 with $50 million in funding to develop AI-driven "Biostaged Medicines" that target specific stages of disease progression, particularly in metabolic, neurodegenerative, inflammatory, and autoimmune diseases, as well as pre-cancer conditions.[1][2][3][4][5] The company builds the Temporal Biodynamics platform, an AI system that integrates multimodal data—like electronic health records, single-cell omics, and real-world evidence from sources such as the U.K. Biobank—to model temporal changes in disease biology, predict progression risk, identify stage-specific biomarkers (BioStage Markers), and enable preemptive therapies that intervene before symptoms become irreversible.[1][3][4][5] Etiome serves patients with chronic progressive diseases by addressing unmet needs in conditions like metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease, Alzheimer's, Parkinson's, and rheumatoid arthritis, solving the problem of imprecise disease staging that leads to treatment failures.[2][3][5] Early momentum includes preclinical liver programs, in vitro Alzheimer's research, and a nascent immune pipeline, with recent leadership additions like Chief Scientific Officer Jean Lachowicz in December 2025.[5][6]
Etiome originated in Flagship Pioneering's labs as part of its Preemptive Health and Medicine Initiative, founded in 2021 to pioneer therapies that act on "silent stage" biology before symptoms emerge.[1][4][5] Key founders include Avak Kahvejian, founding CEO and Flagship general partner with expertise in pioneering biotech ventures, and Scott Lipnick, co-founder, president, and Flagship origination partner, whose background spans data science at Harvard and PatientsLikeMe.[1][3][5] The idea emerged from advances in AI, multimodal health data access, and the recognition that traditional "healthy vs. sick" labels overlook continuous disease progression, fueled by Flagship's ambition to create preventive medicines amid stalled pharma successes.[2][3][5] Pivotal early traction came from stealth-mode development of the Temporal Biodynamics platform, trained on clinical trial data and biobanks, enabling the 2025 launch with $50M committed to internal programs and partnerships.[1][5]
Etiome rides the AI-precision medicine wave, capitalizing on post-2021 AI breakthroughs and exploding multimodal datasets (EHRs, omics) to enable dynamic disease mapping amid stagnant outcomes in chronic diseases like neurodegeneration and metabolic disorders.[2][3][5] Timing is ideal: pharma failures in late-stage trials (e.g., due to patient heterogeneity) create demand for biostage insights, while regulatory shifts favor real-world evidence and preemptive therapies.[2][3] Market forces like aging populations, rising MASH/Alzheimer's prevalence, and biobank accessibility amplify this, positioning Etiome to influence ecosystems by partnering for biomarkers and drugs, potentially reshaping trial design and outcomes under Flagship's proven model (e.g., Moderna).[1][2][5]
Etiome is poised to advance its preclinical liver and in vitro neuro programs into partnerships or trials within 1-2 years, expanding the immune pipeline while scaling Temporal Biodynamics for broader applications like pre-cancer.[5] Trends in federated learning, richer omics data, and outcome-based pricing will accelerate adoption, evolving Etiome from stealth biotech to ecosystem shaper via Biostaged Medicines that preempt debility. As Flagship's latest bet on proactive health, it could redefine intervention timing, delivering the healthier futures promised at launch.[4][6]
